Lynx1 Capital Management LP has filed 30 insider transactions across 5 companies since April 2024.
Most recent transaction: a purchase of 520 shares of Korro Bio, Inc. ($KRRO) on March 31, 2026.
Activity breakdown: 30 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Korro Bio, Inc. | $KRRO | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.001 par value per share | 520 | $10.60 | 1,538,296.0000 | 9,417,295 | 0.03% | 0.01% |
| Dec. 23, 2025 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 6232 | $0.90 | 8,019,148.0000 | 129,835,938 | 0.08% | 0.00% |
| Dec. 22, 2025 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 75500 | $0.90 | 8,012,916.0000 | 129,835,938 | 0.95% | 0.06% |
| Dec. 19, 2025 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share ("Common Stock") | 80069 | $0.90 | 7,937,416.0000 | 129,835,938 | 1.02% | 0.06% |
| Oct. 28, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share | 165667 | $8.40 | 8,963,500.0000 | 59,076,259 | 1.88% | 0.28% |
| Oct. 21, 2025 | Neuphoria Therapeutics Inc. | $NEUP | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.00001 par value per share | 639110 | $5.14 | 875,328.0000 | 2,357,613 | 270.56% | 27.11% |
| Oct. 15, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 51500 | $7.94 | 8,615,616.0000 | 59,076,259 | 0.60% | 0.09% |
| Oct. 17, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 32217 | $7.84 | 8,797,833.0000 | 59,076,259 | 0.37% | 0.05% |
| Oct. 16, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 150000 | $8.86 | 8,765,616.0000 | 59,076,259 | 1.74% | 0.25% |
| Oct. 14, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share ("Common Stock") | 15032 | $7.59 | 8,564,116.0000 | 59,076,259 | 0.18% | 0.03% |
| Oct. 9, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 626043 | $6.70 | 8,271,786.0000 | 59,076,259 | 8.19% | 1.06% |
| Oct. 10, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 277298 | $7.36 | 8,549,084.0000 | 59,076,259 | 3.35% | 0.47% |
| Oct. 8, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share ("Common Stock") | 556300 | $6.46 | 7,645,743.0000 | 59,076,259 | 7.85% | 0.94% |
| Sept. 12, 2025 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 19783 | $6.99 | 611,804.0000 | 3,168,933 | 3.34% | 0.62% |
| Sept. 11, 2025 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share (Common Stock) | 325 | $6.96 | 592,021.0000 | 3,168,933 | 0.05% | 0.01% |
| Sept. 15, 2025 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 11900 | $6.99 | 623,704.0000 | 3,168,933 | 1.95% | 0.38% |
| July 24, 2025 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 66423 | $5.71 | 591,696.0000 | 3,168,933 | 12.65% | 2.10% |
| July 22, 2025 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share ("Common Stock") | 13123 | $5.44 | 475,971.0000 | 3,168,933 | 2.84% | 0.41% |
| July 23, 2025 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 49302 | $5.74 | 525,273.0000 | 3,168,933 | 10.36% | 1.56% |
| May 19, 2025 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share ("Common Stock") | 1388794 | $1.20 | 6,746,141.0000 | 111,990,417 | 25.92% | 1.24% |
| May 20, 2025 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 1200000 | $1.20 | 7,946,141.0000 | 111,990,417 | 17.79% | 1.07% |
| Dec. 27, 2024 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share | 373645 | $0.65 | 9,256,953.0000 | 3,146,582 | 4.21% | 11.88% |
| Dec. 26, 2024 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Pre-funded Warrant (right to buy) | 7500000 | $4.00 | 7,500,000.0000 | 118,700,362 | 9999.99% | 6.32% |
| Dec. 13, 2024 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 100000 | $2.90 | 5,357,347.0000 | 118,700,362 | 1.90% | 0.08% |
| Dec. 12, 2024 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share ("Common Stock") | 31800 | $3.01 | 5,257,347.0000 | 118,700,362 | 0.61% | 0.03% |
| Nov. 25, 2024 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share ("Common Stock") | 259998 | $0.56 | 8,686,953.0000 | 3,146,582 | 3.09% | 8.26% |
| Nov. 26, 2024 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 167055 | $0.71 | 8,854,008.0000 | 3,146,582 | 1.92% | 5.31% |
| Nov. 27, 2024 | Passage BIO, Inc. | $PASG | Lynx1 Capital Management LP | TenPercentOwner | P | Common Stock | 29300 | $0.67 | 8,883,308.0000 | 3,146,582 | 0.33% | 0.93% |
| Nov. 15, 2024 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Common stock, $0.0001 par value per share | 947 | $4.34 | 5,225,547.0000 | 118,700,362 | 0.02% | 0.00% |
| April 19, 2024 | TScan Therapeutics, Inc. | $TCRX | Lynx1 Capital Management LP | TenPercentOwner | P | Pre-funded Warrant (right to buy) | 5000000 | $7.13 | 5,000,000.0000 | 65,599,858 | 9999.99% | 7.62% |